The aim of the study was to identify the enzyme(s) involved in the hydrolysis of the ethyl ester prodrug CDP323, as well as to characterize its transesterification in the presence of ethanol with special emphasis on the risks of drug-drug interaction.
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INTRODUCTION
CDP323 is an ethyl ester prodrug of CT7758, a potent carboxylic acid antagonist of α 4β1 (VLA-4) and, to a lesser extent, α 4β7 integrins (Fig 1) . All leukocytes, except neutrophils, constitutively express α 4β1. The endogenous ligand for α 4β1 is VCAM-1, which is expressed on the vascular endothelium, and is up-regulated in response to proinflammatory mediators. Interaction between α 4β1 and VCAM-1 mediates the adhesion of leukocytes to vessel walls, their trans-endothelial migration into the inflamed tissues, and finally their activation. Blocking α 4β1 inhibits leukocyte migration into the CNS, thereby preventing the uncontrolled accumulation of immune cells that release proinflammatory cytokines and tissue-damaging free radicals known to be an important component in demyelination and multiple sclerosis pathogenesis (Davenport and Munday, 2007) .
CDP323 was developed as VLA-4 antagonist prodrug for the treatment of multiple sclerosis (Bailey et al., 2013) . Its development was discontinued in 2009 based on inadequate interim efficacy data in a Phase II clinical trial (Wolf et al., 2013 ).
CDP323 was designed as an ester prodrug to circumvent the low oral bioavailability of the active carboxylic acid moiety CT7758 observed in most animal species (mice, rat, monkey), which was assumed to be due to poor intestinal permeability. The ester prodrug strategy is a popular approach for compounds with unfavorable physicochemical properties, limiting their intestinal permeability (e.g. highly hydrophilic and/or ionized drugs) (Beaumont et al., 2003) . However, development of ester prodrugs as drug candidates is also associated with additional challenges such as species difference in hydrolysis, potential instability in gastro-intestinal tract and in DMD#54049 blood, high inter-and intra-subject variability in disposition which all affect differently the level and tissue of bio-activation
Ester-containing drugs are most frequently cleaved by carboxylic ester hydrolases (E.C.3.1.1) with a prominent role of carboxylesterases (CES, E.C.3.1.1.1) compared to the other esterase subfamilies or cytochrome P450 (Liederer and Borchardt, 2006) .
Mammalian carboxylesterases (Hosokawa et al., 1990; Taketani et al., 2007; Hosokawa, 2008; Williams et al., 2011 ) comprise a multigene family, and the isoenzymes are classified into five main groups with several subgroups (Satoh and Hosokawa, 2006) .
The major carboxylesterases involved in hydrolysis of xenobiotics are hCES1 and hCES2. Although both forms have high mRNA expression in the liver, hCES1 levels exceed those of hCES2 (Satoh et al., 2002) . But most important, the extrahepatic expression differs between hCES1 and hCES2 (Satoh et al., 2002; Hosokawa, 2008) .
The mRNA expression of hCES1 in decreasing order is the stomach, testis, kidney, spleen and colon. It contrasts with hCES2 where it is the colon, small intestine and heart. The differences in mRNA levels in the liver and small intestine parallel differences in functional activity (Imai, 2006) . hCES1 and hCES2 also differ in their substrate specificity. Although hCES1 and hCES2 have overlapping substrate recognition, clear-evidences of ester-based substrate specificity has been observed (Satoh et al., 2002) . In general, hCES1 accommodates substrates with a large acyl moiety whereas hCES2 favors substrates with a large alcohol substituent (Laizure et al., 2013) .
Carboxylesterases efficiently catalyze the hydrolysis of a variety of ester and amidecontaining compounds such as cocaine (Kamendulis et al., 1996; Pindel et al., 1997) ,
heroin (Kamendulis et al., 1996; Pindel et al., 1997) , CPT-11 (Humerickhouse et al., DMD#54049 6 2000) , temocapril (Imai et al., 2005) , benzoic acid derivatives , clopidogrel (Tang et al., 2006) , oseltamivir and methylphenidate (Sun et al., 2004) .
These enzymes are known to show inter-species variability in their activity and distribution, which complicates the preclinical pharmacological and toxicological evaluation of ester prodrugs. As an example, dog intestine expresses very limited carboxylesterase activity compared to other species (Taketani et al., 2007; Williams et al., 2011) .
In addition, genetic polymorphism has been reported for CES genes which impacts on the bioactivation of ester prodrugs in human (Tarkiainen et al., 2012) , especially in terms of inter-individual variability in drug disposition (Zhu and Markowitz, 2013 ).
The present study aimed to identify the enzymes involved in the hydrolysis of CDP323 with a specific focus on CES isoforms in order to better predict potential risk for drugdrug interaction as well as inter-subject variability as a result of genetic polymorphism.
Taking advantage of the specific tissue distribution of these two enzymes, experiments were carried out in intestinal and liver microsomes. During the frame of preliminary assays using liver microsomes, it was discovered that CDP323 was prone to transesterification when methanol was present in the incubation medium. This observation triggered additional investigations to understand the potential impact of the transesterification on the disposition of CDP323, with a special emphasis on the risk of in vivo drug-drug interaction with ethanol.
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MATERIALS AND METHODS
Chemicals and Reagents.
Loperamide, proadifen, bw284c51, DTNB, benzyl, BNPP, ethopropazine and verapamil were purchased from Sigma (Bornem, Belgium 
Analytical Methods
The HPLC system used was an Agilent 1100 Series (Agilent Technologies, Santa Clara, CA, USA) coupled with a Quattro Micro mass spectrometer. The analytical column was a Sunfire C18 (50 x 2.1mm, 3.5µm), operated at 30°C. Analyses were performed with a gradient method from 100% A to 10%A/90%B in 8 minutes. Eluent A was 0.1% formic acid/acetonitrile (90/10;v/v) and eluent B was 0.1% formic acid/acetonitrile (10/90;v/v).
For metabolite identification, full-scan and product ion scan monitoring using electrospray ionization was used while for analytes quantification, multiple reaction monitoring in positive-ion mode with electrospray ionization was used. Deuterated transester (d 5 -CDP323), it was assumed to have a similar mass response as CDP323.
Data acquisition and the analytical parameters including the selection of ions for each compound were performed by the application software, MassLynx 4.1 (Waters Ltd., Hertfordshire, UK). The concentrations were determined by the peak area ratio method.
Data analysis
Substrate (S) concentrations and corresponding rates (pmol/min/mg protein) from individual experiments were analyzed by nonlinear regression with Grafit software (version 6.0.4, Erithacus Software Limited, Surrey, UK) fitting the data to the full nonlinear form of the two enzyme equation (1) 
+ =
Where CL int, vivo (mL/min/kg) was obtained from (6) and a hepatic blood flow (Q H ) of 22 mL/min/kg was used. 
RESULTS
Initially, CDP323 (1µM -MH
+ 549) was incubated with HLM in the presence and absence of NADPH. In presence of NADPH, four major metabolites were observed, one being the hydrolyzed product CT7758 (MH + 521) coming from the cleavage of the ethyl ester bond (Fig 1) . Two hydroxylated metabolites were detected (hydroxylation on bromolactone moiety and hydroxylation of the naphthyridine ring) as well as a metabolite with a protonated molecular ion at m/z 535. In NADPH-free conditions, only the hydrolyzed product (CT7758) and the metabolite m/z 535 were observed.
These preliminary investigations demonstrated that other metabolites were observed in addition to the expected one (CT7758, hydrolyzed product). Based on mass difference, this later metabolite m/z 535 should correspond either to the loss of methylene from parent or to the addition of methyl to CT7758. As shown in Figure 2 occurred mainly in the liver, these in vitro intrinsic clearance were scaled up to the in vivo hepatic clearance using the well-stirred model and estimating a free fraction of CDP323 in human plasma (fu) at 0.045 (data on UCB files). As shown in Table 2 , the predicted value of CL H remained close to the hepatic blood flow . As a result of this blood-flow limited clearance, ethanol demonstrated moderate effect on CL H (30% reduction at 2% ethanol) (see Table 2 ).
To further characterize the observed transesterification of CDP323, incubations were transesterification from the same experiment presented in Figure 5 (formation of transester, d5-CDP323) are given in Table 3 . In NADPH-free conditions, the clearance of CDP323 is explained by its hydrolysis into CT7758 as shown by the similar intrinsic clearance calculated from disappearance rate of CDP323 and formation rate of CT7758.
In presence of 0.5% ethanol, both intrinsic clearance (i.e. CDP323 consumption and This article has not been copyedited and formatted. The final version may differ from this version. CT7758 formation) decreased in a similar way. This observed decrease clearance of CDP323 is likely resulting from the formation of trans-ester which is, in this case, the parent drug and is not due to a "true" inhibition of the enzyme involved in CDP323
clearance. To demonstrate this hypothesis, d 6 -ethanol was used to allow the quantification of the formation of the transester (d5-CDP323). In presence of 0.5% deuterated ethanol, the intrinsic clearance calculated on disappearance rate of CDP323
was roughly similar to the one measured in absence of ethanol suggesting that ethanol did not decrease the disappearance rate of CDP323. Moreover, the formation rate of CT7758 was similar to the one in presence of 0.5% ethanol. Of interest, the sum of both formation rates (transester [d5-CDP323] and CT7758) quantitatively accounts for the disappearance rate of CDP323 and also the formation rate of CT7758 in ethanol-free conditions. Also, one could be stricken by the fact that Clint values obtained in Table 3 differ from those obtained in Table 1 . This is mainly explained by the two different approaches used to determine Clint values. In Table 1 , Clint values were calculated as Vmax/Km and therefore are representative of Clint value when substrate concentration is well below Km value (assumption of equation (2)) while in Phenotyping assays were carried-out to determine the (iso)enzyme(s) involved in CDP323 hydrolysis. As shown in Figure 6 , the hydrolysis rate of CDP323 is approximately 20-fold lower in HIM than in HLM suggesting the preferred involvement of hCES1. Isoenzyme assignment was further confirmed using recombinant hCES1 and hCES2 as shown in Figure 7 . (Yamaori et al., 2006) and were without any inhibitory effect on CDP323 hydrolysis (Figure 8) . Similarly, the hCES2 inhibitor loperamide did not impair the reaction. No specific hCES1 inhibitors are currently available, so non-specific CES inhibitors were used instead i.e. BNPP, paraoxon, benzil (Eng et al., 2010; Jewell et al., 2007; Wadkins et al., 2005) . They all inhibited CDP323 hydrolysis significantly (>80% inhibition).
This article has not been copyedited and formatted. The final version may differ from this version. 
DISCUSSION
In 1958, Adrien Albert used for the first time the term "prodrug" to define a pharmacologically inactive compound that needs to be biotransformed in vivo to release its active moiety (Albert, 1958) . Since that time, prodrug strategy has been a powerful tool in drug development not only to improve the physico-chemical, biopharmaceutical
and pharmacokinetic properties of pharmacologically active compounds but also for ensuring a more specific delivery of the active drug to the action site (Jana et al., 2010; Hsieh et al., 2009; Dalpiaz et al., 2012; Coughlin et al., 2012 as filters).
The ethyl ester prodrug, CDP323, is a prodrug designed to improve the intestinal absorption of the active carboxylic acid containing VLA4-antagonist CT7758. CDP323
was designed, characterized and developed for the treatment of multiple sclerosis.
The present in vitro work aimed at further exploring the hydrolysis of CDP323 by investigating its kinetic and the enzymes involved in the process. The preliminary investigations on metabolite identification in human liver microsomes demonstrated, as expected, that CDP323 prodrug was mainly hydrolyzed, releasing the carboxylic acid moiety, CT7758. However, this work also pointed out that oxidation of the ester prodrug itself occurred leading to 2 metabolites (hydroxylation on bromolactone moiety and hydroxylation of the naphthyridine ring) but more unexpected, that CDP323 was prone to be transesterified. Trans-esterification occurred during the hydrolysis of the ester prodrug, where the alcohol moiety of the prodrug is replaced by another alcohol present in large excess to generate another ester prodrug instead of the hydrolyzed This article has not been copyedited and formatted. The final version may differ from this version. product (Imai, 2006) . Although there is a huge number of publications on prodrugs, the transesterification mechanism has been so far largely overlooked. Among the scarce reports, the best-known studied example of transesterification is cocaine. As described in vitro and in vivo, in presence of ethanol, cocaine can be transesterified into cocaethylene that is more toxic than cocaine itself (Boyer and Petersen, 1992; Laizure et al., 2003; Bourland et al., 1998) . Other examples of transesterification observed in vitro included clopidrogel (Tang et al., 2006) , meperidine (Bourland et al., 1997) and methylphenidate (Bourland et al., 1997; Markowitz et al., 2000) . Interestingly, Patrick et al (Patrick et al., 2013; Patrick et al., 2007) showed in human volunteers that the transesterification of methylphenidate was enantioselective, l-methylphenidate being transesterified into l-ethylphenidate without any d-ethylphenidate formed. As shown in the present study, transesterification can occur quite easily in vitro, questioning the use of alcohols (like ethanol, methanol) as organic solvents to solubilize ester-containing drugs. This could lead to the formation of an artefactual transester metabolite and , could bias the hydrolysis rate determination. In the present study, the observed transester metabolite corresponded to a methylester because incubations were carried out in presence of methanol. Such transesterification with methanol should not occur in vivo given the very low levels of methanol observed in the liver. In human subjects, the only exogenous alcohol that could typically reach a high concentration is ethanol. High levels of ethanol could potentially trigger two kinds of drug-drug interaction with ester prodrugs. First, and probably the most critical, is the formation of a new transester metabolite different from the parent drug (thus should not be a concern for ethylester prodrugs). Such drug-drug interaction would be of major concern since patients could be exposed to a non-characterized metabolite (ethylester prodrug) which could cause unpredicted pharmacological activity or toxicity (as reported earlier with cocaine).
However, as described in the present study, this potential risk could be proactively addressed measuring transesterification in vitro. Since endogenous alcohols (eg.
glycerol, cholesterol, glucose) are present at relatively high plasma concentrations (up to 1mM) (Maggs et al., 1995) , one might also question whether they could also produce transesterification as observed with ethanol if we assumed liver concentrations reached similar levels than those observed in plasma . Crow et al (Crow et al., 2010) recently showed that endogenous alcohol like oxysterols had inhibitory properties on CES highlighting that these endogenous alcohol are also able to interact with CES; however potential transesterification was not investigated.
Secondly, interaction with ethanol could also results in a decrease of the formation rate of the hydrolyzed product and concomitant apparent decrease of the ester prodrug clearance (in the case of ethylester prodrug). Ethanol plasma levels in human subjects can rise up to 0.1 to 0.2% v/v without major safety issues. Assuming that ethanol liver concentrations are in equilibrium with plasma levels, such concentration showed, in the present in vitro assays, marginal effects, if any, on CDP323 transformation. Accordingly, the risk that significant clinical drug-drug interaction occurred between ethanol and CDP323 is regarded as highly unlikely.
In the present in vitro study, in order to explore the mechanism behind the interaction between ethanol and CDP323, ethanol concentrations that are not clinically relevant (up to 2%) were tested. In these conditions, the Km and Vmax values describing CDP323 hydrolysis significantly and dose-dependently decreased in the presence of ethanol.
However, these two parameters were not affected to a the same extent, resulting in a impact on intrinsic clearance is a typical signature of an uncompetitive inhibition where the inhibitor binds to the enzyme-substrate complex (Shou et al., 2001) . In the special case of transesterification, we believe that the interaction between alcohol and CES is of uncompetitive nature meaning that ethanol interacts with enzyme substrate complex.
Indeed, it's known that transesterification occurred during the second step of the hydrolysis process when alcohol is in abundance and can interact with substrate-enzyme complex to release the trans-ester instead of the carboxylic acid (for an in depth description see review of Imai et al (Imai, 2006) ) . In order to understand the reason of this decrease formation rate of CT7758 in presence of ethanol, , deuterated ethanol (d6-ethanol) was used to allow the detection and quantification of the transester formed (d5-CDP323) by exchange of the ethyl function with d6-ethanol (Chen et al., 2004) . This experiment was very helpful and useful to dissect and understand the trans-esterification mechanism. . As expected based on Km/Vmax experiment, formation rate of CT7758 was decreased to the same extent in both incubations with ethanol or d6-ethanol. Also in both conditions, the formation of CT7758 (incubation with ethanol) or the sum of formation rates of CT7758 and d5-CDP323 (incubation with d6-ethanol) accounted for the disappearance rate of CDP323.
The main difference between incubation with ethanol or with d6-ethanol was observed on the disappearance rate of CDP323. Indeed, compared to control, an apparent However, it is important to state that the latter conclusion will not always translate into a lack of effect of ethanol on the ester prodrug clearance. To make that happen, the transester formed in presence of alcohol should be different than the original ester prodrug. In our case, for example, in clinical use of CDP323 with ethanol, an apparent decrease of CDP323 clearance should be observed since the transester formed will be the same than parent drug. Overall, these data clearly demonstrated that ethanol did not really inhibit the enzyme involved in the hydrolysis but rather promoted the formation of an additional metabolite (transester) which is in competition with the hydrolysis reaction (formation of the hydrolysis product). Similar in vitro observations have been reported for cocaethylene (ethylester of cocaine) incubated in S9 fractions in presence/absence of ethanol (Bourland et al., 1998) . In addition, in vivo evidence with methylphenidate (substrate of hCES1) further confirmed our findings that, in the presence of ethanol, transesterification can occur and that this does not impact the clearance of the ester prodrug itself while formation of its hydrolyzed product (ritalinic acid) was impaired (Koehm et al., 2010) . However, this finding (lack of effect of ethanol on the ester prodrug clearance) is not supported by the data published on the interaction between cocaine and ethanol where it is clearly highlighted that ethanol inhibited clearance of cocaine (Laizure et al., 2003; Parker and Laizure, 2010) . One of the potential reasons is that cocaine is not only cleared by hCES1 but also by hCES2.
Indeed, Crow et al (Crow et al., 2010) observed that ethanol is a potent inhibitor of CES2 meaning that the observed effect of ethanol could be due to inhibition of presystemic clearance mediated by hCES2 (intestine) rather than an effect on systemic clearance mainly mediated by hCES1. This hypothesis is corroborated by the This article has not been copyedited and formatted. The final version may differ from this version. observation that the terminal half-life of cocaine was not impacted by ethanol treatment (Parker and Laizure, 2010) .
The last objective of the study was the identification of the enzyme involved in the hydrolysis of CDP323. The data collected clearly supported hCES1 as the major enzyme involved in the hydrolysis of CDP323 ethyl ester prodrug. Indeed, chemical inhibitors of carboxylesterases (specific to CES2 and non-specific) (Hatfield and Potter, 2011) , as well as the use of recombinant enzyme (hCES1 and hCES2), both demonstrated that hCES1 plays a major role in CP323 hydrolysis. Specific inhibitors of arylesterase, acetylcholine esterase and butyrylcholinesterase were also tested and rule out the involvement of other esterases. In addition, CDP323 was found to be more readily hydrolyzed in liver than in intestinal fraction, consistent with the reported tissue distribution of hCES1. Moreover, CDP323 was demonstrated to be prone to transesterification, a reaction only reported for hCES1 (Imai, 2006) . Finally, the preferred hydrolysis of CDP323 by hCES1 is in line with the known structure-activity relationship of this isoenzyme (Satoh et al., 2002) . As a consequence of CES involvement in drug clearance , one might expect challenging drug development.
Indeed, among others, marked species difference is well described with a predominant role of CES in rodent plasma while not described in dog and human plasma. This make the bioanalysis in rodent plasma quite difficult due to this enzymatic instability. In addition, there are more and more evidence of CES polymorphism impairing pharmacokinetic of ester prodrug requiring therefore special attention in clinical trials (Lewis et al., 2013; Suzaki et al., 2013) .
Overall, the present study unequivocally showed the ability of CDP323, an ethyl ester prodrug, to be transesterified in presence of alcohol. Mechanistic studies demonstrated 
